You have matched to 1 trial

Guest Profile:  No profile selected

Copy link
Sort by zip code: 94107 Hide Map Icon
mail-icon

Register to sign up for Trial Alerts

Receive emails about new trials that match your profile.
1

Vaccine for Metastatic HER2+, HER2 Low, or EGFR+ Breast Cancer

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors

Purpose: To study the safety, best dose, and effects (good and bad) of an experimental HER2 B cell peptide vaccine.

Who is this for?: People with advanced HER2 positive (HER2+), HER2 low, and/or EGFR positive (EGFR+) breast cancer who have received at least 1 line of therapy for advanced disease. You must not have received more than 3 lines of chemotherapy in the last 2 years. View full eligibility criteria

What's involved?

<p class="seamTextPara"> You will receive the following: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 B cell peptide vaccine, by injection, 3 visits within 3 months</li> </ul> <p class="seamTextPara"> followed by: </p> <ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">HER2 B cell peptide vaccine booster, by injection, every 6 months (optional)</li></ul>

What's being studied?

<ul class="seamTextUnorderedList"> <li class="seamTextUnorderedListItem">The HER2 B cell peptide vaccine is an experimental vaccine designed to stimulate your immune system to go after and kill HER2+ cancer cells.</li> <li class="seamTextUnorderedListItem">Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells.</li> <li class="seamTextUnorderedListItem">In this trial, HER2 low is defined as IHC 1+ or 2+.</li> <li class="seamTextUnorderedListItem">This trial is also enrolling people with other types of cancer.</li></ul>

How can I learn more?

<ul class='seamTextUnorderedList'><li class='seamTextUnorderedListItem'>View eligibility criteria and additional trial information: <a href='https://clinicaltrials.gov/ct2/show/NCT06414733' target='_blank'>ClinicalTrials.gov</a> </li><li class='seamTextUnorderedListItem'><a href='https://cancer.iu.edu/patients/clinical-trials/61428' target='_blank'>Indiana University: Trial Information Page</a> </li><li class='seamTextUnorderedListItem'><a href='https://www.breastcancer.org/managing-life/immune-system/vaccines' target='_blank'>Breastcancer.org: Breast Cancer and Vaccines</a> </li></ul>
1

Vaccine for Metastatic HER2+, HER2 Low, or EGFR+ Breast Cancer

Phase Ib Active Immunotherapy Trial (Expansion) With a Combination of Two Chimeric (Trastuzumab-like and Pertuzumab-like) HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors
Icon

Nearest Location:
1946 miles
Indiana University Melvin & Bren Simon Comprehensive Cancer Center
Indianpolis, IN

Icon

Visits:
At least 3 visits within 3 months

Icon

ClinicalTrials.gov: NCT06414733

Icon

Phase I

HELP GUIDE
HELP GUIDE